Allen, who lives in New York, has been battling stage 4 synovial sarcoma since July 2020, and she has gained viral attention ...

The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended three novel medicines for approval at its ...

PrimeC has been given an ‘Orphan Drug’ status by the FDA (Food and Drug Administration) and EMA (European Medicines Agency).

A key regulatory win could turn this under-the-radar treatment into AbbVie's next billion-dollar success story.

Vertex Pharmaceuticals (NASDAQ:VRTX) announced Friday that an expert panel of the EU drug regulator, the European Medicines ...

NewAmsterdam Pharma's obicetrapib lowers LDL-C in Phase 3 trials, showing promise as a CETP inhibitor. Read more on NAMS ...

McKinsey report says Indian pharma rose to global prominence led by export boom & improved compliance: Shardul Nautiyal, Mumbai Saturday, March 1, 2025, 08:00 Hrs [IST] McKinsey & ...

The global generic oncology drugs market is set for consistent growth over the next decade, with sales anticipated to rise from USD 23,743.5 million in 2025 to USD 30,606.3 million by 2035, reflecting ...

Investorideas , a global news source and expert investing resource, announces today's roundup of stocks added to the biotech stock directory.

February brought policy updates and several biosimilar approvals, including the first FDA approval for an insulin aspart ...

Developed by Johnson & Johnson, guselkumab (GUS) is the first approved fully-human, dual-acting IL-23p19 subunit inhibitor that blocks IL-23 and binds to CD64, a receptor on cells that produce IL-23.

If approved, this off-the-shelf, fixed-duration Columvi combination will be the first bispecific antibody regimen available for patients with DLBCL following relapse ...